NASDAQ:NTGN Neon Therapeutics (NTGN) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free NTGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.07▼$3.0750-Day Range$2.77▼$3.0752-Week Range$0.88▼$6.25VolumeN/AAverage Volume516,108 shsMarket Capitalization$88.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neon Therapeutics alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Neon Therapeutics Stock (NASDAQ:NTGN)Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 NTGN Stock News HeadlinesApril 9, 2024 | seekingalpha.comBCYC Bicycle Therapeutics plcFebruary 20, 2024 | investing.comNTGN_old Historical DataApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 22, 2023 | seekingalpha.comNBCO Neon Bloom, Inc.March 1, 2023 | theguardian.comMacbeth review – neon-tinted remix plays like a cinematic thrillerSee More Headlines Receive NTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/02/2020Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NTGN CUSIPN/A CIKN/A Webwww.neontherapeutics.com Phone617-337-4701FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-199.09% Return on Assets-137.14% Debt Debt-to-Equity Ratio0.43 Current Ratio1.58 Quick Ratio3.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.14Miscellaneous Outstanding Shares28,967,000Free FloatN/AMarket Cap$88.93 million OptionableNot Optionable Beta-0.81 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Hugh O'Dowd (Age 54)Pres, CEO & Director Dr. Eric S. Lander (Age 62)Founder & Director Dr. Yasir B. Al-Wakeel (Age 37)Chief Financial Officer Dr. Richard Gaynor (Age 69)Pres of R&D Dr. Edward Fritsch Ph.D.Founder and Chief Technology OfficerKey CompetitorsCurisNASDAQ:CRISProtalix BioTherapeuticsNYSE:PLXAlloVirNASDAQ:ALVRAtara BiotherapeuticsNASDAQ:ATRASangamo TherapeuticsNASDAQ:SGMOView All Competitors NTGN Stock Analysis - Frequently Asked Questions How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) announced its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.03. What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Pfizer (PFE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), T2 Biosystems (TTOO) and Vaxart (VXRT). When did Neon Therapeutics IPO? Neon Therapeutics (NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager. This page (NASDAQ:NTGN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.